HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

estradiol-drospirenone combination

consists of 17beta-estradiol and drospirenone; used to treat menopause

Also Known As:

Angeliq

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Drug Context: Research Results

Experts

1.	Coksuer, Cengiz: 1 article (05/2011)
2.	Coksuer, Hakan: 1 article (05/2011)
3.	Keskin, Nadi: 1 article (05/2011)
4.	Koplay, Mustafa: 1 article (05/2011)
5.	Oghan, Fatih: 1 article (05/2011)
6.	Ozveren, Olcay: 1 article (05/2011)
7.	Foidart, J-M: 1 article (10/2005)

Related Diseases

1.	Body Weight (Weight, Body) 10/01/2005 - "Clinical studies with an oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany) and a new continuous combined oral hormone replacement therapy (HRT) containing 1 mg 17beta-estradiol and 2 mg drospirenone (Angeliq, Schering AG) were all designed specifically to evaluate treatment effects on body weight and cardiovascular function, both of which can be influenced by aldosterone receptor antagonism. "
2.	Vertigo (Positional Vertigo) 05/01/2011 - "Oral daily treatment with Angeliq reduces CIMT and climacteric complaints including vertigo/dizziness in postmenopausal women. " 05/01/2011 - "To investigate the effects of Angeliq on hormonal, metabolic, biochemical and cardiovascular profile, carotid intima-media thickness (CIMT) and vertigo/dizziness symptoms in postmenopausal women. "
3.	Uterine Hemorrhage (Uterine Bleeding) 06/16/2015 - "Before treatment, the level of E2 was (12 ± 10) ng/L, triglyceride (TG) (2.0 ± 1.1) mmol/L, lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L, (1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2. After 12-week treatment, (30 ± 18) ng/L, (1.6 ± 1.1) mmol/L and (37 ± 36) mmol/L in group 1 versus (23 ± 9) ng/L, (1.1 ± 0.6) mmol/L and (18 ± 12) mmol/L in group 2. A greater incidence of vaginal bleeding and thicker endometrium were found in group 1. Angeliq can relieve menopausal symptoms. "
4.	Dizziness (Lightheadedness) 05/01/2011 - "Oral daily treatment with Angeliq reduces CIMT and climacteric complaints including vertigo/dizziness in postmenopausal women. " 05/01/2011 - "To investigate the effects of Angeliq on hormonal, metabolic, biochemical and cardiovascular profile, carotid intima-media thickness (CIMT) and vertigo/dizziness symptoms in postmenopausal women. "

Related Drugs and Biologics

1.	Mineralocorticoid Receptors (Mineralocorticoid Receptor)
2.	Oral Contraceptives
3.	drospirenone and ethinyl estradiol combination (Yasmin)
4.	drospirenone
5.	Lipoprotein(a)
6.	Triglycerides (Triacylglycerol)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)